The MAGNETOM Viato.Mobile may facilitate improved access to MRI capabilities for patients with serious health conditions who lack geographic proximity to centers with advanced imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the MAGNETOM Viato.Mobile, a 1.5 Tesla magnetic resonance imaging (MRI) system that is reportedly designed for easy transportation to off-site locations.
The 70 centimeter-bore scanner offers a variety of features including BioMatrix Technology and Deep Resolve image reconstruction, according to Siemens Healthineers, the manufacturer of MAGNETOM Viato.Mobile.
The company said the artificial intelligence (AI)-powered Deep Resolve technology accelerates scan times for brain scans by up to 70 percent, enhances image resolution and improves signal-to-noise ratio. Siemens Healthineers added that BioMatrix Technology prevents variation in imaging results by enabling clinicians to personalize MRI exams and compensate for different patient anatomies and physiologies.
Jane Kilkenny, the vice president of magnetic resonance at Siemens Healthineers North America, said the MAGNETOM Viato.Mobile represents an opportunity to bring the capabilities of advanced imaging to patients who don’t have geographic proximity to facilities with these imaging systems.
“The MAGNETOM Viato.Mobile demonstrates our dedication to the mobile MR market by offering the latest and greatest technologies to patients who might lack convenient access to premium diagnostic MR scanners,” noted Kilkenny. “The introduction of the MAGNETOM Viato.Mobile is yet another example of our efforts to democratize high-end imaging technology to provide greater access to care.”
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.